Related Experiment Videos
Ridogrel in the setting of percutaneous transluminal coronary angioplasty
C Timmermans1, M Vrolix, J Vanhaecke
1Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.
Insights
This study found that combining heparin and ridogrel therapy during percutaneous transluminal coronary angioplasty (PTCA) showed promising antiplatelet efficacy and manageable safety. Ridogrel significantly reduced thromboxane B2 and prevented acute reocclusions compared to standard aspirin treatment.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) requires effective antiplatelet strategies to prevent complications.
- The combination of heparin and antiplatelet agents is standard, but novel agents are explored for improved efficacy and safety.
Purpose of the Study:
- To evaluate the safety and antiplatelet efficacy of combined heparin and ridogrel therapy in patients undergoing PTCA.
- To compare the incidence of acute reocclusions and bleeding complications with standard aspirin therapy.
Main Methods:
- 32 patients undergoing PTCA received intravenous ridogrel followed by oral doses, along with a continuous heparin infusion.
- Serum thromboxane B2 and 6-keto-prostaglandin F1 alpha levels were measured.
- Bleeding events, need for blood transfusion, emergency bypass surgery, and acute reocclusions were recorded.
Main Results:
- Heparin and ridogrel therapy demonstrated effective inhibition of thromboxane B2 and increased prostacyclin levels.
- No acute reocclusions were observed in the ridogrel group, contrasting with 5.6% in the standard aspirin group.
- Bleeding complications occurred in 13 patients, with only 2 requiring blood transfusion; one patient needed emergency bypass surgery without hemostasis issues.
Conclusions:
- The combination of heparin and ridogrel is safe and effective in preventing acute reocclusions during PTCA.
- Ridogrel offers a favorable antiplatelet profile compared to aspirin in this setting.
- Further clinical follow-up at 6 months indicated favorable outcomes for patients treated with ridogrel.
Abstract:
The safety of the combination of heparin and ridogrel therapy and its antiplatelet efficacy was examined in the setting of percutaneous transluminal coronary angioplasty (PTCA). In 32 patients without known aspirin intake for 10 days before PTCA, therapy with ridogrel (300-mg intravenous bolus) was begun just before PTCA and continued orally at a dose of 300 mg twice daily until discharge. Heparin was administered as a 10,000 IU bolus dose before PTCA and followed by an intravenous infusion at a rate of 1,000 IU/hour for 24 hours. Bleeding problems at the arterial entry site occurred in 13 patients, which required a blood transfusion in only 2 patients. One patient underwent emergency bypass surgery without specific problems of hemostasis. Ridogrel virtually eliminated thromboxane B2 from the serum (29,990 +/- 6,555 pg/0.1 ml before vs 63 +/- 7 pg/0.1 ml at 2 hours after ridogrel), with a concomitant increase in serum 6-keto-prostaglandin F1 alpha (511 +/- 34 pg/0.1 ml before vs 1,190 +/- 146 pg/0.1 ml at 24 hours after ridogrel). There were no acute reocclusions in the ridogrel-treated patients, whereas acute reocclusions occurred in 5.6% of the patients taking the standard aspirin + heparin regimen during the same period. Furthermore, at 6-month clinical follow-up patients treated with ridogrel compared favorably with those receiving standard treatment.